{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:26:09Z","timestamp":1773833169565,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical outcomes are unknown after ticagrelor treatment in patients with end-stage renal disease (ESRD) who are diagnosed with acute myocardial infarction (AMI). ESRD patients who were on hemodialysis and received dual antiplatelet therapy (DAPT) for AMI between July 2013 and December 2016 were identified in Taiwan's National Health Insurance Research Database. Using stabilized inverse probability of treatment weighting, patients receiving aspirin plus ticagrelor (n\u2009=\u2009530) were compared with those receiving aspirin plus clopidogrel (n\u2009=\u20092462) for the primary efficacy endpoint, a composite of all-cause death, nonfatal myocardial infarction, or nonfatal stroke, and bleeding, defined according to the Bleeding Academic Research Consortium. Study outcomes were compared between the two groups using Cox proportional hazards model or competing risk model for the hazard ratio or subdistribution hazard ratio (SHR). During 9\u00a0months of follow-up, ticagrelor was comparable to clopidogrel with respect to the risks of primary efficacy endpoint [11.69 vs. 9.28\/100 patient-months; SHR, 1.16; 95% confidence interval (CI) 0.97\u20131.4] and bleeding (5.55 vs. 4.36\/100 patient-months; SHR 1.14; 95% CI 0.88\u20131.47). In conclusion, among hemodialysis patients receiving DAPT for AMI, ticagrelor was comparable to clopidogrel with regard to the composite efficacy endpoint and bleeding.<\/jats:p>","DOI":"10.1038\/s41598-021-00360-0","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T10:04:42Z","timestamp":1634810682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study"],"prefix":"10.1038","volume":"11","author":[{"given":"Ying-Chang","family":"Tung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Rou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Tai","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"1","key":"360_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","volume":"116","author":"EL Schiffrin","year":"2007","unstructured":"Schiffrin, E. L., Lipman, M. L. & Mann, J. F. Chronic kidney disease: Effects on the cardiovascular system. Circulation 116(1), 85\u201397 (2007).","journal-title":"Circulation"},{"issue":"13","key":"360_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C.-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296\u20131305 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"360_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jacc.2011.07.010","volume":"58","author":"AS Go","year":"2011","unstructured":"Go, A. S. et al. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J. Am. Coll. Cardiol. 58(15), 1600\u20131607 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"360_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1097\/01.ASN.0000069165.79509.42","volume":"14","author":"P Stenvinkel","year":"2003","unstructured":"Stenvinkel, P., Pecoits-Filho, R. & Lindholm, B. Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J. Am. Soc. Nephrol. 14(7), 1927\u20131939 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"360_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"CS Fox","year":"2010","unstructured":"Fox, C. S. et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the national cardiovascular data acute coronary treatment and intervention outcomes network registry. Circulation 121(3), 357\u2013365 (2010).","journal-title":"Circulation"},{"issue":"12","key":"360_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJM199809173391203","volume":"339","author":"CA Herzog","year":"1998","unstructured":"Herzog, C. A., Ma, J. Z. & Collins, A. J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. Med. 339(12), 799\u2013805 (1998).","journal-title":"N. Engl. Med."},{"issue":"05","key":"360_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1055\/s-0037-1613462","volume":"89","author":"I M\u00fcller","year":"2003","unstructured":"M\u00fcller, I. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89(05), 783\u2013787 (2003).","journal-title":"Thromb. Haemost."},{"issue":"14","key":"360_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505\u20131516 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"360_CR9","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry, U. S. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62(24), 2261\u20132273 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"360_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel, P. A. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J. Am. Coll. Cardiol. 46(10), 1827\u20131832 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"360_CR11","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","volume":"49","author":"P Buonamici","year":"2007","unstructured":"Buonamici, P. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312\u20132317 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9892","key":"360_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone, G. W. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 382(9892), 614\u2013623 (2013).","journal-title":"Lancet"},{"issue":"3","key":"360_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1538-7836.2005.01751.x","volume":"4","author":"T Cuisset","year":"2006","unstructured":"Cuisset, T. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4(3), 542\u2013549 (2006).","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"360_CR14","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1093\/ndt\/gft103","volume":"28","author":"T Gremmel","year":"2013","unstructured":"Gremmel, T. et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol. Dial. Transpl. 28(8), 2116\u20132122 (2013).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"360_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","volume":"155","author":"PJ Best","year":"2008","unstructured":"Best, P. J. et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during observation (CREDO) trial. Am. Heart J. 155(4), 687\u2013693 (2008).","journal-title":"Am. Heart J."},{"issue":"4","key":"360_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1681\/ASN.2010020220","volume":"22","author":"P Htun","year":"2011","unstructured":"Htun, P. et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J. Am. Soc. Nephrol. 22(4), 627\u2013633 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"25","key":"360_CR17","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"P Gurbel","year":"2009","unstructured":"Gurbel, P. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study. Circulation 120(25), 2577 (2009).","journal-title":"Circulation"},{"issue":"11","key":"360_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"360_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James, S. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 122(11), 1056\u20131067 (2010).","journal-title":"Circulation"},{"key":"360_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"C-Y Hsieh","year":"2019","unstructured":"Hsieh, C.-Y. et al. Taiwan\u2019s National Health Insurance Research Database: Past and future. Clin. Epidemiol. 11, 349 (2019).","journal-title":"Clin. Epidemiol."},{"issue":"6","key":"360_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"C-L Cheng","year":"2014","unstructured":"Cheng, C.-L. et al. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J. Epidemiol. 24(6), 500\u2013507 (2014).","journal-title":"J. Epidemiol."},{"issue":"3","key":"360_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng, C. L., Kao, Y. H. Y., Lin, S. J., Lee, C. H. & Lai, M. L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug Saf. 20(3), 236\u2013242 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"360_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"C-L Cheng","year":"2015","unstructured":"Cheng, C.-L., Chien, H.-C., Lee, C.-H., Lin, S.-J. & Yang, Y.-H.K. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance research database in Taiwan. Int. J. Cardiol. 201, 96\u2013101 (2015).","journal-title":"Int. J. Cardiol."},{"issue":"23","key":"360_CR24","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation 123(23), 2736\u20132747 (2011).","journal-title":"Circulation"},{"issue":"2","key":"360_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu, S. et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2), 273\u2013277 (2010).","journal-title":"Value Health"},{"issue":"19","key":"360_CR26","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey, D. F. et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat. Med. 32(19), 3388\u20133414 (2013).","journal-title":"Stat. Med."},{"issue":"3","key":"360_CR27","doi-asserted-by":"publisher","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","volume":"6","author":"BK Lee","year":"2011","unstructured":"Lee, B. K., Lessler, J. & Stuart, E. A. Weight trimming and propensity score weighting. PLoS ONE 6(3), e18174 (2011).","journal-title":"PLoS ONE"},{"issue":"6","key":"360_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat.-Simul. C 38(6), 1228\u20131234 (2009).","journal-title":"Commun. Stat.-Simul. C"},{"issue":"446","key":"360_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94(446), 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"issue":"2","key":"360_CR30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","volume":"14","author":"M Keltai","year":"2007","unstructured":"Keltai, M. et al. Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur. J. Cardiovasc. Prev. Rehabil. 14(2), 312\u2013318 (2007).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"10","key":"360_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","volume":"103","author":"A Dasgupta","year":"2009","unstructured":"Dasgupta, A. et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am. J. Cardiol. 103(10), 1359\u20131363 (2009).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"360_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/j.ajkd.2011.10.045","volume":"59","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos, D. et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am. J. Kidney Dis. 59(3), 469\u2013471 (2012).","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"360_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2018.07.001","volume":"73","author":"Y Ohno","year":"2019","unstructured":"Ohno, Y. et al. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. J. Cardiol. 73(1), 51\u201357 (2019).","journal-title":"J. Cardiol."},{"issue":"9","key":"360_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1177\/0091270011415526","volume":"52","author":"K Butler","year":"2012","unstructured":"Butler, K. & Teng, R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J. Clin. Pharmacol. 52(9), 1388\u20131398 (2012).","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"360_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ajkd.2012.05.001","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos, D. et al. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am. J. Kidney Dis. 60(2), 332\u2013333 (2012).","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"360_CR36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","volume":"65","author":"KH Jeong","year":"2015","unstructured":"Jeong, K. H. et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: A randomized crossover study. Am. J. Kidney Dis. 65(6), 916\u2013924 (2015).","journal-title":"Am. J. Kidney Dis."},{"issue":"19","key":"360_CR37","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","volume":"104","author":"R Edfors","year":"2018","unstructured":"Edfors, R. et al. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart 104(19), 1575\u20131582 (2018).","journal-title":"Heart"},{"issue":"31","key":"360_CR38","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban, P. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for high bleeding risk. Eur. Heart J. 40(31), 2632\u20132653 (2019).","journal-title":"Eur. Heart J."},{"issue":"22","key":"360_CR39","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.jacc.2008.12.073","volume":"53","author":"BJ Doyle","year":"2009","unstructured":"Doyle, B. J., Rihal, C. S., Gastineau, D. A. & Holmes, D. R. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: Implications for contemporary practice. J. Am. Coll. Cardiol. 53(22), 2019\u20132027 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"360_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Impact of bleeding on mortality after percutaneous coronary intervention: Results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc. Interv. 4(6), 654\u2013664 (2011).","journal-title":"JACC Cardiovasc. Interv."},{"issue":"2","key":"360_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/cpt.2011","volume":"109","author":"CJ Chang","year":"2021","unstructured":"Chang, C. J. et al. Efficacy and safety of ticagrelor vs. clopidogrel in East Asian patients with acute myocardial infarction: A nationwide cohort study. Clin. Pharmacol. Ther. 109(2), 443\u2013451 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"360_CR42","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","volume":"79","author":"S Goto","year":"2015","unstructured":"Goto, S., Huang, C.-H., Park, S.-J., Emanuelsson, H. & Kimura, T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome\u2013randomized, double-blind, phase III PHILO study. Circ. J. 79(11), 2452\u20132460 (2015).","journal-title":"Circ. J."},{"issue":"23","key":"360_CR43","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","volume":"140","author":"D-W Park","year":"2019","unstructured":"Park, D.-W. et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: A randomized clinical trial. Circulation 140(23), 1865\u20131877 (2019).","journal-title":"Circulation"},{"issue":"1","key":"360_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: A systematic review and meta-analysis. Circulation 135(1), 21\u201333 (2017).","journal-title":"Circulation"},{"issue":"5","key":"360_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","volume":"16","author":"Y-H Jeong","year":"2014","unstructured":"Jeong, Y.-H. \u201cEast asian paradox\u201d: Challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome. Curr. Cardiol. Rep. 16(5), 485 (2014).","journal-title":"Curr. Cardiol. Rep."},{"issue":"2","key":"360_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/01.ASN.0000043140.23422.4F","volume":"14","author":"SK Ganesh","year":"2003","unstructured":"Ganesh, S. K., Hulbert-Shearon, T., Port, F. K., Eagle, K. & Stack, A. G. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J. Am. Soc. Nephrol. 14(2), 415\u2013424 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"360_CR47","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.116.024637","volume":"134","author":"MP Bonaca","year":"2016","unstructured":"Bonaca, M. P. et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation 134(12), 861\u2013871 (2016).","journal-title":"Circulation"},{"key":"360_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jns.2018.05.001","volume":"390","author":"K Malhotra","year":"2018","unstructured":"Malhotra, K. et al. Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis. J. Neurol. Sci. 390, 212\u2013218 (2018).","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"360_CR49","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1681\/ASN.2015050535","volume":"27","author":"AO Molnar","year":"2016","unstructured":"Molnar, A. O. et al. The risk of major hemorrhage with CKD. J. Am. Soc. Nephrol. 27(9), 2825\u20132832 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"14","key":"360_CR50","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","volume":"64","author":"M Hamon","year":"2014","unstructured":"Hamon, M. et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J. Am. Coll. Cardiol. 64(14), 1430\u20131436 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"360_CR51","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino, G. et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol. 68(17), 1851\u20131864 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10073","key":"360_CR52","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 389(10073), 1025\u20131034 (2017).","journal-title":"Lancet"},{"issue":"1","key":"360_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1145-0","volume":"16","author":"A Covic","year":"2018","unstructured":"Covic, A. et al. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med. 16(1), 1\u201311 (2018).","journal-title":"BMC Med."},{"issue":"22","key":"360_CR54","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1001\/jama.2009.1800","volume":"302","author":"TT Tsai","year":"2009","unstructured":"Tsai, T. T. et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 302(22), 2458\u20132464 (2009).","journal-title":"JAMA"},{"issue":"5","key":"360_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2215\/CJN.12120720","volume":"16","author":"TA Mavrakanas","year":"2021","unstructured":"Mavrakanas, T. A., Kamal, O. & Charytan, D. M. Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure. Clin. J. Am. Soc. Nephrol. 16(5), 757\u2013764 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"360_CR56","doi-asserted-by":"crossref","unstructured":"Li, Y. S., Wang, S. H., Hwang, S. J., Yang, Y. H. & Hsieh, K. P. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Br. J. Clin. Pharmacol. (2021).","DOI":"10.1111\/bcp.14935"},{"issue":"20","key":"360_CR57","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"360_CR58","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.04260413","volume":"8","author":"GA Block","year":"2013","unstructured":"Block, G. A., Kilpatrick, R. D., Lowe, K. A., Wang, W. & Danese, M. D. CKD\u2013mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 8(12), 2132\u20132140 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"360_CR59","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.amjcard.2011.07.015","volume":"108","author":"RF Storey","year":"2011","unstructured":"Storey, R. F. et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). Am. J. Cardiol. 108(11), 1542\u20131546 (2011).","journal-title":"Am. J. Cardiol."},{"issue":"19","key":"360_CR60","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.jacc.2010.11.056","volume":"57","author":"BM Scirica","year":"2011","unstructured":"Scirica, B. M. et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (platelet inhibition and patient outcomes) trial: Results of the continuous electrocardiographic assessment substudy. J. Am. Coll. Cardiol. 57(19), 1908\u20131916 (2011).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00360-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:50:40Z","timestamp":1670086240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00360-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00360-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20826"}}